Drug intelligence / Profile preview

MWTX-06

Development stage: Preclinical
Lead developer: Mabwell Therapeutics
Modality: Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

MWTX-06 is a first-in-class bifunctional therapeutic being developed by Mabwell Therapeutics for the treatment of various muscle-wasting and neuromuscular disorders. Developed using the proprietary MyoDock™ platform, MWTX-06 features a dual mechanism of action designed to simultaneously stimulate muscle growth and enhance neuromuscular junction (NMJ) function. This approach aims to address both the physical degeneration of muscle tissue and the underlying signaling dysfunction between nerves and muscles. The drug is currently in the discovery stage for a broad range of indications, including Duchenne muscular dystrophy (DMD), myotonic dystrophy, facioscapulohumeral muscular dystrophy (FSHD), and disuse-induced muscle atrophy.

Beyond the preview

Go deeper on MWTX-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MWTX-06.

Explore the full profile